Arrowhead to Report Fiscal 2013 First Quarter Financial Results

  Arrowhead to Report Fiscal 2013 First Quarter Financial Results

        - Conference Call Scheduled for Wednesday, February 13, 2013 -

Business Wire

PASADENA, Calif. -- February 6, 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics
company, today announced that it will report its financial results for the
fiscal 2013 first quarter ended December 31, 2012, on Wednesday, February 13,
2013 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the
conference call, please dial 877-317-6789 (toll free from the US),
866-605-3852 (toll free from Canada), or 412-317-6789 (for international
callers). Investors may also access a live audio webcast of this conference
call on the Company's website at www.arrowheadresearch.com.

A replay of the webcast will be available approximately two hours after the
conclusion of the call and will remain available for 90 days. An audio replay
will also be available approximately one hour after the conclusion of the call
and will be available for 30 days. The audio replay can be accessed by dialing
877-344-7529 (toll free from the US and Canada), or 412-317-0088 (for
international callers) and entering Event ID 10024948.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage targeted therapeutics
company with development programs in oncology, obesity, and chronic hepatitis
B virus infection. The company is leveraging its platform technologies to
design and develop peptide-drug conjugates (PDCs) that specifically home to
cell types of interest while sparing off-target tissues, create targeted drugs
based on the gene silencing RNA interference (RNAi) mechanism, and work with
partners to create improved versions of traditional small molecule drugs.

For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to ir@arrowres.com

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based upon our current expectations and speak
only as of the date hereof. Our actual results may differ materially and
adversely from those expressed in any forward-looking statements as a result
of various factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our ability to
successfully develop drug candidates, the timing for starting and completing
clinical trials, rapid technological change in our markets, and the
enforcement of our intellectual property rights. Arrowhead Research
Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We assume
no obligation to update or revise forward-looking statements to reflect new
events or circumstances.

Contact:

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
or
The Trout Group
Lauren Glaser, 646-378-2972
ir@arrowres.com
 
Press spacebar to pause and continue. Press esc to stop.